|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KCNK1 |
Gene summary for KCNK1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KCNK1 | Gene ID | 3775 |
| Gene name | potassium two pore domain channel subfamily K member 1 | |
| Gene Alias | DPK | |
| Cytomap | 1q42.2 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | A0A024R3T2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3775 | KCNK1 | Pat22-B | Human | Stomach | GC | 3.43e-37 | -9.88e-02 | -0.1042 |
| 3775 | KCNK1 | Pat24-B | Human | Stomach | GC | 2.96e-07 | -3.22e-01 | -0.1184 |
| 3775 | KCNK1 | Pat25-A | Human | Stomach | CAG with IM | 3.80e-31 | -3.06e-01 | -0.1648 |
| 3775 | KCNK1 | Pat26-A | Human | Stomach | CSG | 2.52e-37 | -3.19e-01 | -0.2402 |
| 3775 | KCNK1 | Pat28-A | Human | Stomach | CSG | 1.58e-10 | -2.95e-01 | -0.2594 |
| 3775 | KCNK1 | Pat29-A | Human | Stomach | CAG with IM | 5.19e-06 | -3.50e-01 | -0.2769 |
| 3775 | KCNK1 | NAG_2 | Human | Stomach | CSG | 3.91e-04 | 1.54e-01 | -0.3324 |
| 3775 | KCNK1 | CAG_3 | Human | Stomach | CAG | 4.05e-06 | -3.34e-01 | -0.2766 |
| 3775 | KCNK1 | WIM_2 | Human | Stomach | WIM | 2.07e-02 | -5.02e-01 | 0.1159 |
| 3775 | KCNK1 | SIM_1 | Human | Stomach | SIM | 2.31e-02 | -4.58e-01 | 0.3573 |
| 3775 | KCNK1 | SIM_2 | Human | Stomach | SIM | 1.14e-07 | -5.71e-01 | 0.3139 |
| 3775 | KCNK1 | SIM_4 | Human | Stomach | SIM | 1.25e-02 | -4.83e-01 | 0.2664 |
| 3775 | KCNK1 | EGC | Human | Stomach | GC | 3.22e-06 | -5.22e-01 | 0.1683 |
| 3775 | KCNK1 | male-WTA | Human | Thyroid | PTC | 4.95e-05 | 6.50e-02 | 0.1037 |
| 3775 | KCNK1 | PTC01 | Human | Thyroid | PTC | 8.01e-12 | 1.92e-01 | 0.1899 |
| 3775 | KCNK1 | PTC04 | Human | Thyroid | PTC | 2.20e-10 | 2.16e-01 | 0.1927 |
| 3775 | KCNK1 | PTC05 | Human | Thyroid | PTC | 7.06e-16 | 5.27e-01 | 0.2065 |
| 3775 | KCNK1 | PTC06 | Human | Thyroid | PTC | 2.13e-29 | 7.27e-01 | 0.2057 |
| 3775 | KCNK1 | PTC07 | Human | Thyroid | PTC | 1.37e-28 | 3.93e-01 | 0.2044 |
| 3775 | KCNK1 | ATC13 | Human | Thyroid | ATC | 1.04e-02 | 2.51e-02 | 0.34 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00423912 | Breast | IDC | regulation of membrane potential | 49/1434 | 434/18723 | 4.04e-03 | 3.25e-02 | 49 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KCNK1 | SNV | Missense_Mutation | novel | c.405N>G | p.Ile135Met | p.I135M | O00180 | protein_coding | deleterious(0) | possibly_damaging(0.771) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| KCNK1 | SNV | Missense_Mutation | c.619G>C | p.Glu207Gln | p.E207Q | O00180 | protein_coding | deleterious(0) | benign(0.354) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| KCNK1 | SNV | Missense_Mutation | novel | c.46N>T | p.Arg16Trp | p.R16W | O00180 | protein_coding | tolerated(0.08) | benign(0.18) | TCGA-AC-A8OQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KCNK1 | SNV | Missense_Mutation | novel | c.253G>T | p.Ala85Ser | p.A85S | O00180 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-EW-A3U0-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| KCNK1 | SNV | Missense_Mutation | novel | c.286G>A | p.Ala96Thr | p.A96T | O00180 | protein_coding | tolerated(0.36) | benign(0.005) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| KCNK1 | SNV | Missense_Mutation | novel | c.685N>A | p.Gly229Arg | p.G229R | O00180 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A9V1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| KCNK1 | SNV | Missense_Mutation | c.362G>A | p.Gly121Asp | p.G121D | O00180 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| KCNK1 | SNV | Missense_Mutation | c.289N>C | p.Ser97Pro | p.S97P | O00180 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| KCNK1 | SNV | Missense_Mutation | rs776795446 | c.730N>T | p.Leu244Phe | p.L244F | O00180 | protein_coding | deleterious(0.02) | possibly_damaging(0.826) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| KCNK1 | SNV | Missense_Mutation | c.860A>G | p.Asp287Gly | p.D287G | O00180 | protein_coding | tolerated(0.06) | benign(0) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |